LÓPEZ JARAMILLO, JOSÉ PATRICIO

Preferred name

Main Affiliation

Facultad de Ciencias de la Salud Eugenio Espejo

CENIEC - Grupo de Investigación de Enfermedades Crónicas

Web Site

Google Scholar

ORCID

0000-0002-9122-8742

Scopus Author ID

7004478068

Now showing 1 - 10 of 38

Some of the metrics are blocked by your
consent settings
Core outcome sets for trials of interventions to prevent and to treat multimorbidity in adults in low and middle-income countries: the COSMOS study
(BMJ, 2024-08)
Aishwarya Lakshmi Vidyasagaran
;
Rubab Ayesha
;
Jan R Boehnke
;
Jamie Kirkham
;
Louise Rose
Introduction The burden of multimorbidity is recognised increasingly in low- and middle-income countries (LMICs), creating a strong emphasis on the need for effective evidence-based interventions. Core outcome sets (COS) appropriate for the study of multimorbidity in LMICs do not presently exist. These are required to standardise reporting and contribute to a consistent and cohesive evidence-base to inform policy and practice. We describe the development of two COS for intervention trials aimed at preventing and treating multimorbidity in adults in LMICs. Methods To generate a comprehensive list of relevant prevention and treatment outcomes, we conducted a systematic review and qualitative interviews with people with multimorbidity and their caregivers living in LMICs. We then used a modified two-round Delphi process to identify outcomes most important to four stakeholder groups (people with multimorbidity/caregivers, multimorbidity researchers, healthcare professionals and policymakers) with representation from 33 countries. Consensus meetings were used to reach agreement on the two final COS. Registration: https://www.comet-initiative.org/Studies/Details/1580. Results The systematic review and qualitative interviews identified 24 outcomes for prevention and 49 for treatment of multimorbidity. An additional 12 prevention and 6 treatment outcomes were added from Delphi round 1. Delphi round 2 surveys were completed by 95 of 132 round 1 participants (72.0%) for prevention and 95 of 133 (71.4%) participants for treatment outcomes. Consensus meetings agreed four outcomes for the prevention COS: (1) adverse events, (2) development of new comorbidity, (3) health risk behaviour and (4) quality of life; and four for the treatment COS: (1) adherence to treatment, (2) adverse events, (3) out-of-pocket expenditure and (4) quality of life. Conclusion Following established guidelines, we developed two COS for trials of interventions for multimorbidity prevention and treatment, specific to adults in LMIC contexts. We recommend their inclusion in future trials to meaningfully advance the field of multimorbidity research in LMICs. PROSPERO registration number CRD42020197293.
Scopus© Citations 9
Some of the metrics are blocked by your
consent settings
Manejo de los pacientes con diabetes en la época de COVID-19: Recomendaciones prácticas
(Saber CDCH-UCV, 2020-08-10)
José López López
;
LOPEZ JARAMILLO, JOSÉ PATRICIO
<jats:p>La nueva enfermedad COVID-19 es causada por el beta coronavirus SARS-CoV-2. Los primeros casos de neumonía grave se registraron en China a finales de diciembre de 2019. La enfermedad se ha expandido rápidamente en todo el mundo y tiene un amplio espectro de manifestaciones clínicas, desde sujetos asintomáticos hasta pacientes que desarrollan enfermedad multisistémica grave y muerte. Se ha demostrado que la hipertensión y la diabetes son más frecuentes en las personas con COVID-19 y que la presencia de diabetes se asocia con mayor severidad de la enfermedad y peores desenlaces. En el presente artículo revisamos los posibles mecanismos por los cuales los pacientes diabéticos tienen un mayor riesgo para presentar mayor mortalidad por COVID-19 y sugerimos acciones preventivas que deben ser seguidas por la población en general y particularmente por los pacientes diabéticos.</jats:p>
Scopus© Citations 2
Some of the metrics are blocked by your
consent settings
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial
(Elsevier BV, 2018-01)
Stuart J Connolly
;
John W Eikelboom
;
Jackie Bosch
;
Gilles Dagenais
;
Leanne Dyal
Scopus© Citations 386
Some of the metrics are blocked by your
consent settings
Diet and Clinical Outcomes in a Heart Failure Population
(Elsevier BV, 2026-04)
Joseph, Philip
;
Dehghan, Mahshid
;
Ezekowitz, Justin A.
;
Miller, Victoria
;
Lanas, Fernando
Scopus© Citations 2
Some of the metrics are blocked by your
consent settings
Evaluación del perfil cardiometabólico en profesionales de salud de Latinoamérica
(Elsevier BV, 2021-07)
Ivetteh Gaibor-Santos
;
Jennifer Garay
;
Daniela A. Esmeral-Ordoñez
;
Diana Rueda-García
;
Daniel D. Cohen
Scopus© Citations 2
Some of the metrics are blocked by your
consent settings
2026 Latin American consensus for the management of patients with hypertension and cardio-renal and metabolic disturbances: endorsed by the Latin American Society of Hypertension, the Iberoamerican Hypertension League, and the World Hypertension League
(Ovid Technologies (Wolters Kluwer Health), 2026-03-17)
Coca, Antonio
;
Sánchez, Ramiro
;
Molina de Salazar, Dora I.
;
Peñaherrera, Ernesto
;
Alcocer, Luis
Scopus© Citations 1
Some of the metrics are blocked by your
consent settings
2024 Latin American Society of Hypertension guidelines on the management of arterial hypertension and related comorbidities in Latin America
(Ovid Technologies (Wolters Kluwer Health), 2025-01-03)
Ramiro Sánchez
;
Antonio Coca
;
Dora I. Molina de Salazar
;
Luis Alcocer
;
Dagnovar Aristizabal
Hypertension is responsible for more than two million deaths due to cardiovascular disease annually in Latin America (LATAM), of which one million occurs before 70 years of age. Hypertension is the main risk factor for cardiovascular morbidity and mortality, affecting between 20 and 40% of LATAM adults. Since the publication of the 2017 LASH hypertension guidelines, reports from different LATAM countries have confirmed the burden of hypertension on cardiovascular disease events and mortality in the region. Many studies in the region have reported and emphasized the dramatically insufficient blood pressure control. The extremely low rates of awareness, treatment, and control of hypertension, particularly in patients with metabolic disorders, is a recognized severe problem in LATAM. Earlier implementation of antihypertensive interventions and management of all cardiovascular risk factors is the recognized best strategy to improve the natural history of cardiovascular disease in LATAM. The 2024 LASH guidelines have been developed by a large group of experts from internal medicine, cardiology, nephrology, endocrinology, general medicine, geriatrics, pharmacology, and epidemiology of different countries of LATAM and Europe. A careful search for novel studies on hypertension and related diseases in LATAM, together with the new evidence that emerged since the 2017 LASH guidelines, support all statements and recommendations. This update aims to provide clear, concise, accessible, and useful recommendations for health professionals to improve awareness, treatment, and control of hypertension and associated cardiovascular risk factors in the region.
Scopus© Citations 27
Some of the metrics are blocked by your
consent settings
La realidad del riesgo cardiovascular en Iberoamérica
(Elsevier BV, 2020-10)
LOPEZ JARAMILLO, JOSÉ PATRICIO
;
José López-López
;
Salim Yusuf
Scopus© Citations 6
Some of the metrics are blocked by your
consent settings
External validation and comparison of six cardiovascular risk prediction models in the Prospective Urban Rural Epidemiology (PURE)-Colombia study
(Oxford University Press (OUP), 2025-06-07)
Lopez-atalaya Jose P.
;
Ángel A. Garcia-Peña
;
Martinez-bello Daniel
;
Gonzalez Ana M.
;
Maritza Perez-Mayorga
AbstractTo externally validate the SCORE2, AHA/ACC pooled cohort equation (PCE), Framingham Risk Score (FRS), Non-Laboratory INTERHEART Risk Score (NL-IHRS), Globorisk-LAC, and WHO prediction models and compare their discrimination and calibration capacity. Methods and results Validation in individuals aged 40–69 years with at least 10 years of follow-up and without baseline use of statins or cardiovascular diseases from the Prospective Urban Rural Epidemiology (PURE)-Colombia prospective cohort study. For discrimination, the C-statistic, and receiver operating characteristic curves with the integrated area under the curve (AUCi) were used and compared. For calibration, the smoothed time-to-event method was used, choosing a recalibration factor based on the integrated calibration index (ICI). In the NL-IHRS, linear regressions were used. In 3802 participants (59.1% women), baseline risk ranged from 4.8% (SCORE2 women) to 55.7% (NL-IHRS). After a mean follow-up of 13.2 years, 234 events were reported (4.8 cases per 1000 person-years). The C-statistic ranged between 0.637 (0.601–0.672) in NL-IHRS and 0.767 (0.657–0.877) in AHA/ACC PCE. Discrimination was similar between AUCi. In women, higher over-prediction was observed in the Globorisk-LAC (61%) and WHO (59%). In men, higher over-prediction was observed in FRS (72%) and AHA/ACC PCE (71%). Overestimations were corrected after multiplying by a factor derived from the ICI. Conclusion Six prediction models had a similar discrimination capacity, supporting their use after multiplying by a correction factor. If blood tests are unavailable, NL-IHRS is a reasonable option. Our results suggest that these models could be used in other countries of Latin America after correcting the overestimations with a multiplying factor.
Scopus© Citations 20
Some of the metrics are blocked by your
consent settings
Single-pill combination therapy is the standard of care for hypertension, but it is time for the next step: Implementation
(Elsevier BV, 2024-12)
Jose P. Lopez-Lopez
;
LOPEZ JARAMILLO, JOSÉ PATRICIO
The GMRx2 trial1 in adults with high blood pressure (BP) demonstrated that after 12 weeks, a low-dose single-pill combination of telmisartan, amlodipine, and indapamide significantly reduced BP levels compared to several dual combinations (telmisartan with amlodipine, telmisartan with indapamide, or amlodipine with indapamide). Adverse events did not differ between the groups. This novel therapeutic option could improve high BP control

LÓPEZ JARAMILLO, JOSÉ PATRICIO

Filters

Settings

Sort By

Results per page